Doxorubicin and covalently crosslinked doxorubicin derivatives binding to purified cardiac thin-filament proteins in vitro

William Lewis, Kevin Beckenstein, Lawrence Shapiro, Saul Puszkin

Research output: Contribution to journalArticlepeer-review

12 Citations (Scopus)

Abstract

The binding of cardiac actin and tropomyosin to a cardiotoxic antineoplastic agent, doxorubicin, and its covalently crosslinked derivatives was investigated. The primary amino group of the daunosamine moiety of doxorubicin was blocked with fluorescein isothiocyanate. This doxorubicin derivative did not bind to Sepharose which was conjugated with cardiac actin. A doxorubicin dimer was made by covalently crosslinking one doxorubicin molecule to another identical doxorubicin molecule through the free amino group of each daunosamine moiety. This derivative demonstrated mobility different from parent doxorubicin on thin-layer chromatography, different elution pattern by column chromatography, and did not show binding affinity for actin. Exploring other purified thin-filament proteins, it was found that doxorubicin did bind to tropomyosin when gel filtration was performed on the protein drug mixture. The ability of tropomyosin to form paracrystal in vitro was not disturbed by a variety of concentrations of doxorubicin. These data support the concept that the doxorubicin solitary free amino group is the site which is responsible for this ligand to bind to actin and may relate to its cardiotoxic effects.

Original languageEnglish
Pages (from-to)64-73
Number of pages10
JournalExperimental and Molecular Pathology
Volume43
Issue number1
DOIs
Publication statusPublished - Aug 1985

Bibliographical note

Funding Information:
William Lewis is recipient of a Clinical Investigator Award from the NHLBI, K8 HL 01295. This work was supported in part by the California Institute for Cancer Research, Los Angeles, California and in part by the Cancer Research Coordinating Committee, Berkeley, California.

Funding

William Lewis is recipient of a Clinical Investigator Award from the NHLBI, K8 HL 01295. This work was supported in part by the California Institute for Cancer Research, Los Angeles, California and in part by the Cancer Research Coordinating Committee, Berkeley, California.

FundersFunder number
California Institute for Cancer Research

    ASJC Scopus Subject Areas

    • Pathology and Forensic Medicine
    • Molecular Biology
    • Clinical Biochemistry

    Fingerprint

    Dive into the research topics of 'Doxorubicin and covalently crosslinked doxorubicin derivatives binding to purified cardiac thin-filament proteins in vitro'. Together they form a unique fingerprint.

    Cite this